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Original Basic Science—Liver
Background. Preconditioning of donor livers before organ retrieval may improve organ quality after transplantation. We 
investigated whether preconditioning with metformin reduces preservation injury and improves hepatobiliary function in rat 
donor livers during ex situ normothermic machine perfusion (NMP) and after orthotopic liver transplantation. Methods. 
Lewis rats were administered metformin via oral gavage, after which a donor hepatectomy was performed followed by a 
standardized cold storage period of 4 hours. Graft assessment was performed using NMP via double perfusion of the hepatic 
artery and portal vein. In an additional experiment, rat donor livers preconditioned with metformin were stored on ice for 4 
hours and transplanted to confirm postoperative liver function and survival. Data were analyzed and compared with sham-
fed controls. Results. Graft assessment using NMP confirmed that preconditioning significantly improved ATP production, 
markers for hepatobiliary function (total bile production, biliary bilirubin, and bicarbonate), and significantly lowered levels 
of lactate, glucose, and apoptosis. After orthotopic liver transplantation, metformin preconditioning significantly reduced 
transaminase levels. Conclusions. Preconditioning with metformin lowers hepatobiliary injury and improves hepatobiliary 
function in an in situ and ex situ model of rat donor liver transplantation.
(Transplantation 2020;104: e271–e280).
INTRODUCTION
Metformin, a well-known drug for antihyperglycemic ther-
apy in patients with type II diabetes mellitus, has also been 
shown to have beneficial effects in reducing ischemia-reper-
fusion (I/R) injury.1 Several animal and human studies have 
shown that administration of metformin before an ischemic 
event (preconditioning) reduces tissue injury and preserves 
cardiac function after myocardial infarction.2-4
Although the exact protective mechanism of metformin 
during I/R injury is not fully known, one of the main 
actions of metformin is to partially and selectively inhibit 
complex I of the mitochondrial respiratory chain.5 This 
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inhibition of complex I has positive and negative conse-
quences. Positively, inhibition of complex I reduces the 
level of cellular energy, which stimulates phosphorylation 
of the cellular energy sensor enzyme AMP protein kinase 
(AMPK).6 An indirect consequence of AMPK activation 
is prevention of opening of the mitochondrial permeabil-
ity transition pore in the mitochondrial inner membrane.7 
When the mitochondrial permeability transition pores 
are closed, it is not possible to leak cytochrome c, which 
normally activates apoptotic death pathways.8 Another 
positive effect of partial complex I inhibition is a reduc-
tion in the production of reactive oxygen species (ROS).9 
Some ROS production normally accompanies oxidative 
phosphorylation and this increases during reperfusion. 
ROS avidly attack and degrade many cellular components 
including the mitochondria themselves. Inhibition of oxida-
tive phosphorylation by metformin is coupled with lower 
ROS production and the mitochondria will be better pro-
tected against ROS-mediated injury.9 On the other hand, a 
negative effect of metformin and AMPK activation is the 
downregulation of the nuclear bile acid farnesoid X recep-
tor (FXR).10 FXR plays a central role in the control of bile 
salt homeostasis, maintaining the balance between bile 
salt synthesis and transport. FXR regulates expression of 
cholesterol 7α-hydroxylase (CYP7A10), the rate-limiting 
enzyme in bile salt synthesis, and the bile salt export pump 
(BSEP), the major bile salt exporter.11 In addition, it has 
been shown that repression of the FXR transporter during 
ischemic conditions contributes to biliary epithelial injuries 
by disturbing bile acids transport in cholangiocytes after 
rat liver transplantation.12
One of the current challenges in liver transplantation is the 
shortage of available donor livers. A widely adopted strategy 
to increase the number of donors is the use of extended cri-
teria donor (ECD) livers.13 However, these ECD livers are 
more prone to I/R injury and are therefore related to lower 
graft survival rates.13 To enhance outcome after transplanta-
tion of ECD livers, quality of the organ can be improved 
before procurement with preconditioning strategies.14
The aim of this study was to investigate whether met-
formin as a preconditioning agent is able to reduce pres-
ervation injury and improves hepatobiliary function. First, 
we administered metformin to rats before donation and 
performed hepatobiliary viability assessment using ex-
situ normothermic machine perfusion (NMP, perfusion 
at 37°C). In an additional experiment, metformin pre-
conditioned rat donor livers were transplanted and after 
48 h, survival and hepatobiliary injury and function were 




Male Lewis rats (LEW/HanHsd) (270–300 g) were obtained 
from Harlan Laboratories (Boxmeer, the Netherlands). 
Animals received care according to the Dutch Law on 
Animal Experiments. The study protocol was approved by 
the Institutional Animal Care and Use Committee of the 
University of Groningen (DEC no. 6708A-C).
Experimental Design
The study consisted of 2 experimental groups and 2 
reference groups (n = 4–6 per group) (Figure  1). The 2 
experimental groups consisted of preconditioning with 
metformin, followed by NMP or transplantation and were 
compared with groups sham-fed with saline.
Metformin was purchased from Sigma-Aldrich 
(1,1-dimethyl biguanide hydrochloride, Sigma-Aldrich 
Inc., St. Louis, MO). For assessment of the precondition-
ing effects, metformin (300 mg/kg body weight) was dis-
solved in saline (0.9% NaCl) and administered 12 and 2 h 
before the hepatectomy directly into the stomach via oral 
gavage. Pretreatment with metformin in a dose of 300 mg/
kg body weight is in accordance with earlier rat studies 
wherein adequate serum levels were obtained (metformin 
therapeutic range 1–4 mg/L).15,16 All other groups were 
only fed with saline (0.9% NaCl) at the same time points 
(sham feeding) before the hepatectomy.
In all study groups, livers were procured from living 
donors (see next paragraph) and subsequently preserved by 
static cold storage (SCS) in histidine-tryptophan-ketoglut-
arate (HTK) preservation solution (Custodiol, Essential 
Pharmaceuticals, Ewing, NJ) for 4 h. Before NMP, all liv-
ers were flushed with 10 mL of cold saline.
As described before,17,18 the basic NMP perfusion fluid 
consisted of 25 mL human red blood cell concentrate (final 
hematocrit 25%; Sanquin, Amsterdam, the Netherlands), 
53.9 mL William’s Medium E solution, 20 mL human albumin 
(200 g/L Albuman, Sanquin, Amsterdam, the Netherlands), 
1 mL insulin (100 IE/mL Actrapid, Novo Nordisk, Alphen 
aan den Rijn, the Netherlands), and 0.1 mL unfractionated 
heparin (5000 IE/mL, Heparin LEO Pharma,  Amsterdam, 
the Netherlands), adding up to a total volume of 100 mL.
FIGURE 1. Schematic representation of the experimental groups to examine the effect of metformin as preconditioning agent during 
normothermic machine perfusion (NMP) and after rat liver transplantation. All donor liver recipients survived the 48 h postoperative 
observation period without complications. HTK, histidine-tryptophan-ketoglutarate; SCS, static cold storage.
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Procurement of Rat Livers From Living Donors 
During NMP
Procurement of rat livers from living donors is described 
previously.17,18 In brief, inhalation anesthesia with isoflu-
rane and oxygen was used before and during the procure-
ment (2%–3% isoflurane). After the laparotomy, the large 
bile duct was cannulated and 1 mL 0.9% NaCl with 500 
IU of heparin was administered via the dorsal penile vein. 
Moreover, a blood sample was taken via the dorsal vein for 
assessment of the serum level of metformin in situ (see next 
paragraph for analysis metformin). After heparinization, 
the hepatectomy was performed by ligation of the splenic 
vein, mesenteric artery, and mesenteric vein cannulation of 
the celiac trunk. After clamping the infra-hepatic vena cava 
and the portal vein, the portal vein was cannulated and via 
the portal vein cannula, the liver was flushed in situ with 
10 mL 0.9% NaCl (37°C). Subsequently, the supra-hepatic 
vena cava was transected, followed by a cold flush out with 
5 mL HTK preservation solution (4°C) via the portal vein 
cannula. The liver was removed and flushed with an addi-
tional 20 mL of cold (4°C) HTK via the portal vein cannula 
and 5 mL of cold (4°C) HTK via the hepatic artery (celiac 
trunk cannula) before preservation by SCS.
SCS and NMP
For SCS, livers were stored in bags with ice-cold HTK 
(4°C) on melting ice for 4 h. Ex  situ NMP of rat donor 
livers was performed with a liver machine perfusion sys-
tem that enabled dual perfusion via both the hepatic artery 
and the portal vein using a closed circuit (Figure 2). Our 
research group has already used this experimental set-up in 
earlier experiments.17,18 In brief, the system was pressure-
controlled by a computer algorithm (provided by Organ 
Assist, Groningen, the Netherlands) allowing autoregula-
tion of blood through the liver, with a constant pressure 
at variable flow rates. In-line sensors monitored pressure 
and flow. Ex situ NMP was performed with a mean arterial 
pressure of 110 and 11 mm Hg at portal side.
Orthotopic Liver Transplantation
Similar to the NMP experiment, donor rats were sub-
jected to oral gavage with metformin 12 and 2 h before 
the hepatectomy or sham-fed with saline at the same time 
intervals. After the hepatectomy, donor livers were stored 
on ice for 4 h in HTK solution. Thereafter, these livers 
were orthotopically transplanted in weight-matched recipi-
ents as described previously without reconstruction of the 
hepatic artery.19 In brief, the hepatectomy took 30 min, 
the anhepatic time was kept below 20 min and the reper-
fusion phase was performed within 20 min. After 48 h, a 
reoperation in the recipient was performed to obtain blood 
samples for determination of serum levels of aspartate ami-
notransferase (AST), lactate dehydrogenase (LDH), and 
bilirubin. Thereafter, the animals were terminated and liver 
tissue was harvested and stained with hematoxylin and 
eosin (H&E) for further pathological analysis.
Biomolecular Assays
Samples of heparinized arterial blood during the differ-
ent procedures were centrifuged (2700 g for 5 min at 4°C) 
FIGURE 2. Ex situ rat liver machine perfusion system. Two roller pumps provide a continuous flow to the portal vein (A) and a pulsatile 
flow to the hepatic artery (B). Pulses in the portal flow were eliminated with elastic tubing and a pulse damper (C). Two tubular membrane 
oxygenators provide oxygenation of the perfusion solution, as well as removal of CO2 (D). Several bubble traps (3-way connectors) 
were used to eliminate air bubbles in the perfusion solution (E). Flow (Φ) and pressure (P) were detected by in-line sensors and data 
were analyzed and displayed in real time on a connected laptop (F). The perfusion temperature was maintained constant by 2 heat 
exchangers (G) and a radiator/ventilator combination (H), all connected to the thermostat pump (I). For real time control of the perfusion 
temperature, 1 in-line temperature sensor (T) was connected to the thermostat pump. The isolated box encapsulated the perfusion 
system (J) preventing loss of warm or cold air. The rat liver was placed into an organ chamber (K). Bile was collected in Eppendorf tubes 
(L). By the 3-way connecter at the portal side, samples of the perfusion solution were taken every 30 min for analysis of the perfusate (M).
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and the supernatant was collected, frozen, and stored at 
−80°C for future additional analysis. Metformin was meas-
ured by a validated liquid chromatography–tandem mass 
spectrometry method in the laboratory of the Department 
of Clinical Pharmacy and Pharmacology of the University 
Medical Center Groningen. Insulin serum levels were 
analyzed using an ELISA kit (Rat/Mouse Insulin ELISA, 
Merck, Billerica, MA). Determination of glucose, lactate, 
AST, LDH, and bilirubin was performed using standard 
biochemical methods.
Bile production was measured gravimetrically at 30-min 
intervals by weighing Eppendorf tubes in which bile was col-
lected from the biliary drain. The density of bile was defined 
as 1 mg/mL. The hepatic bile production was calculated as 
milliliter per gram liver. Biliary epithelial cell function was 
assessed by measuring pH and bicarbonate concentration in 
bile.17,18 For this purpose, bile samples were collected under 
mineral oil and analyzed immediately using an ABL800 
FLEX analyzer (Radiometer, Brønshøj, Denmark). Biliary 
concentration of γ-glutamyl transferase (γ-GT) and LDH 
was measured as biomarkers of biliary epithelial cell 
injury,17,18 and biliary bilirubin concentration was measured 
as biomarker of hepatocellular secretory function,17,18 using 
standard biochemical methods. Total bile salt concentrations 
were measured as described previously.20
Thiobarbituric acid reactive substances were measured 
in perfusate samples after 2 h of reperfusion, as a marker 
for oxidative stress (degree of lipid peroxidation of mem-
branes) as described before.17
Caspase-3 Enzyme Activity Assay
Directly after SCS and after 3 h of NMP, caspase-3 
enzyme activity was measured in liver parenchyma as 
described previously.21 In brief, the arbitrary fluorescence 
unit was corrected for total protein content. Protein con-
centration was determined using a commercially available 
kit (Bio-Rad, Veenendaal, the Netherlands).
RNA Isolation and Polymerase Chain Reaction
Immediately after SCS and after 3 h of NMP, hepatic 
mRNA expression of hepatocellular transporter protein 
BSEP and cholesterol 7α-hydroxylase (gene symbol CYP7A1) 
was determined by quantitative real-time polymerase chain 
reaction (PCR). RNA isolation, reverse transcription PCR, 
and quantitative PCR were performed as described previ-
ously,22 and 18S mRNA levels were used as endogenous 
control. Primers and probes are provided in Table 1.
ATP Extraction and Measurement
Liver tissue biopsies after 3 h of NMP were immediately 
frozen in liquid nitrogen and were processed later for ATP 
measurement, as described before.17
Statistical Analysis
Continuous variables were presented as median with 
interquartile range (IQR) and were compared using the 
Mann-Whitney U test. The level of significance was set 
at P < 0.05. All statistical analyses were performed using 
SPSS software version 22.0 for Windows (SPSS, Inc., 
Chicago, IL).
RESULTS
Metformin Preconditioning Resulted in Equal Levels 
of Glucose and Insulin But Higher Levels of Lactate 
Before Hepatectomy
Oral administration of metformin caused serum levels 
of ca. 5 mg/mL before hepatectomy (Figure 3A). Glucose 
and insulin levels before the hepatectomy were comparable 
between the metformin preconditioning group and sham-
fed group (saline) (Figure 3B and C). In the group with met-
formin preconditioning, significantly higher levels of lactate 
were found compared with the group with saline precondi-
tioning before hepatectomy (Figure 3D).
Metformin Preconditioning Improved Hepatobiliary 
Function During NMP
Hepatic ATP concentrations (Figure  4A) after 3 h of 
NMP and bile production (Figure 4B) during the whole 
period of NMP were significantly higher in the metformin 
preconditioning group in comparison with saline pre-
conditioning. Bilirubin concentration in bile after 3 h of 
NMP was also significantly higher after metformin pre-
conditioning compared with the group fed with saline 
(Figure 4C).
Bicarbonate concentration (a marker for cholangio-
cyte function) was measured in bile after 1.5 h of NMP 
(Figure  4D). The levels displayed a pattern comparable 
to the biliary bilirubin levels. Metformin preconditioning 
yielded a significantly higher concentration of bicarbonate 
in bile compared with the group with saline as precondi-
tioning agent. Biliary pH levels after 1.5 h of NMP were 
similar between both groups (Figure 4E). Perfusate levels of 
lactate and glucose during NMP are presented in Figure 5A 
and B. In the group with metformin preconditioning, lac-
tate and glucose levels were significantly lower during all 
the different time intervals of NMP, in comparison with 
saline preconditioning.
Metformin Preconditioning Lowered Total 
Concentration of Bile Salts and Reduced BSEP and 
CYP7A1 mRNA Expression
Concentrations of total bile salts after 1.5 h of NMP 
are presented in Figure  6A. The group with metformin 
TABLE 1.
Primer-probe sets used for RT PCR analysis
Gene Sequence
18S Forward: CGG CTA CCA CAT CCA AGG A
Reversed: CCA ATT ACA GGG CCT CGA AA
Probe: CGC GCA AAT TAC CCA CTC CCG A
CYP7A1 Forward: CAG GGA GAT GCT CTG TGT TCA
Reversed: AGG CAT ACA TCC CTT CCG TGA
Probe: TGC AAA ACC TCC AAT CTG TCA TGA GAC CTC C
BSEP Forward: CCA AGC TGC CAA GGA TGC TA
Reversed: CCT TCT CCA ACA AGG GTG TCA
Probe: CAT TAT GGC CCT GCC GCA GCA
BSEP, bile salt exporter; RT PCR, real-time polymerase chain reaction.
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preconditioning displayed a significantly lower concentra-
tion of total bile salts after 1.5 h of NMP compared with 
saline preconditioning.
Relative mRNA expression of CYP7A1 and BSEP imme-
diately measured after SCS (thus before NMP) and after 3 
h of NMP are presented in Figure 6B and C. Before NMP 
metformin preconditioning, significantly decreased mRNA 
levels of CYP7A1 and BSEP were observed compared with 
the groups with saline preconditioning. In addition, after 3 
h of NMP, mRNA levels of CYP7A1 and BSEP were again 
significantly lower in the group with metformin precondi-
tioning compared with the saline preconditioning.
Metformin Preconditioning Did Not Reduce 
Hepatobiliary Injury During NMP
Markers for hepatocellular injury, such as AST and LDH, 
measured hourly during NMP were not significantly differ-
ent between the groups with metformin preconditioning or 
saline preconditioning.
Figure  7A presents caspase-3 activity, a marker for 
apoptosis, measured directly after SCS (thus before 
NMP) and after 3 h of NMP. Before NMP, caspase-3 
activity was significantly lower in the group with met-
formin preconditioning compared with the group with 
saline preconditioning. This difference disappeared after 
3 h of NMP.
Levels of thiobarbituric acid reactive substances, a 
marker for oxidative stress, were not significantly different 
between both groups after NMP (Figure 7B).
Markers for cholangiocyte injury, LDH, and γ-GT, meas-
ured in bile after 3 h of NMP are provided in Figure 7C and 
D. The concentrations of biliary LDH and γ-GT were not 
significantly different between the groups with metformin 
preconditioning and saline preconditioning.
Metformin Preconditioning Reduced Hepatocellular 
Injury After Rat Liver Transplantation
Posttransplant serum levels of AST, a marker for hepato-
cellular injury, were significantly lower in the group of rats, 
that received a rat donor liver preconditioned with met-
formin compared with rats, that received a rat donor liver 
preconditioned with saline after 48 h of survival (Figure 8A). 
No significant differences were found between posttrans-
plant serum levels of LDH (Figure 8B). Also, posttransplant 
serum levels of bilirubin, a hepatocellular function marker, 
were not significantly different in recipients with a precon-
ditioned metformin donor liver in comparison to recipients 
with a donor liver without metformin preconditioning (data 
not shown). Both study groups achieved 100% survival after 
48 h. Figure 9 shows liver parenchyma of both groups stained 
with H&E after 48 h of survival. There were no pathological 
differences observed such as hepatocyte injury and/or necro-




FIGURE 3. Serum levels of metformin, glucose, insulin, and lactate before hepatectomy. A, Serum levels of metformin before 
hepatectomy, the median value was 5.6 mg/L (metformin therapeutic range 1–4 mg/L). In the group without preconditioning, metformin 
levels were undetectable. B, Serum glucose levels before hepatectomy. No significant differences observed. C, Serum insulin levels 
before hepatectomy. No significant differences observed. D, Serum lactate levels before hepatectomy. The median level of lactate was 
significantly higher in the group with metformin preconditioning compared with the group with saline preconditioning (*P < 0.05). Data 
are represented as medians with interquartile range (IQR; error bars).
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DISCUSSION
The aim of the current study was to examine whether 
metformin preconditioning was able to reduce preservation 
injury and improves hepatobiliary function during NMP 
as well as after transplantation of donor rat livers. Our 
study demonstrated that preconditioning with metformin 
during NMP significantly improved hepatobiliary function 
as reflected by an increased ATP content, improved bile, 
bilirubin. and biliary bicarbonate production. In addition, 
metformin preconditioning lowered apoptosis (less cas-
pase-3 activity)  and glucose and lactate production dur-
ing NMP. In the additional transplantation experiment, 
a significantly lower level of the injury marker AST was 
measured in rats that received a donor liver precondi-
tioned with metformin compared with rats that received a 
saline preconditioned donor liver. Combining the results of 
NMP and transplantation model, we suggest that precon-




FIGURE 4. Metabolic parameters for hepatobiliary function during normothermic machine perfusion (NMP). A, Hepatic ATP 
concentrations after 3 h of NMP. Hepatic ATP content was significantly higher in the group with metformin preconditioning compared 
with saline preconditioning (*P < 0.05). B, Bile production during 3 h of NMP at different time intervals. The group with metformin 
preconditioning displayed a significantly higher bile production during all the specific time periods, respectively 60, 120, and 180 min 
(*P < 0.05). C, Biliary bilirubin after 3 h of NMP. Significantly higher concentration of bilirubin was measured in the group with metformin 
preconditioning (*P < 0.05). D, Biliary bicarbonate concentrations after 1.5 h of NMP. A significantly higher concentration of bicarbonate 
was measured in the bile samples in the group with metformin preconditioning vs the group with saline preconditioning (*P < 0.05). E, 
Biliary pH levels after 1.5 h of NMP. Biliary pH was not significantly different between both groups. Data are represented as medians with 
interquartile range (IQR; error bars).
FIGURE 5. Serum lactate and glucose concentrations during normothermic machine perfusion (NMP). A, Serum lactate concentrations 
during 60, 120, and 180 min of NMP. B, Serum glucose concentrations during 60, 120, and 180 min of NMP. In the group with metformin 
preconditioning, serum lactate and glucose levels were significantly lower at 60, 120, and 180 min of NMP in comparison with the saline 
preconditioning (*P < 0.05). Data are represented as medians with interquartile range (IQR; error bars).
© 2020 The Author(s). Published by Wolters Kluwer Health, Inc.  e277Westerkamp et al
A B C
FIGURE 6. Total concentration of bile salts and expression of CYP7A1 and BSEP during NMP. A, concentrations of bile salts 
after 1.5 h of NMP. The group with metformin preconditioning displayed a significantly lower concentration of bile salts after 
1.5 h of NMP (*P < 0.05). B, Relative mRNA expression of CYP7A1. C, Relative mRNA expression of BSEP. mRNA expression 
of CYP7A1 and BSEP in biopsies directly after SCS (thus before NMP) showed that metformin preconditioning significantly 
decreases mRNA levels of CYP7A1 and BSEP compared with the groups with saline preconditioning. In addition, after 3 h of 
NMP, mRNA levels of CYP7A1 and BSEP were significantly lower in the group with metformin preconditioning (#P < 0.05). Data 
are represented as medians with interquartile range (IQR; error bars). BSEP, bile salt export pump; NMP, normothermic machine 
perfusion.
FIGURE 7. Markers of hepatobiliary injury during NMP. A, Caspase-3 activity measured in liver parenchyma after static 
cold storage (SCS; before NMP) and after 3 h of NMP. Caspase-3 activity was significantly lower in the group with 
metformin preconditioning compared with the group with only saline preconditioning before NMP (*P < 0.05). However, after 3 h 
of NMP, no significant differences were found in caspase-3 activity between both groups. B, Perfusate TBARS levels after 3 h of 
NMP. TBARS levels were not significantly different between both groups. C, Biliary LDH after 3 h of NMP. D, Biliary γ-GT after 3 h 
of NMP. The concentrations of biliary LDH and γ-GT were not significantly different between the groups with metformin preconditioning 
and saline preconditioning. Data are represented as medians with interquartile range (IQR; error bars). γ-GT, γ-glutamyl transferase; 
LDH, lactate dehydrogenase; NMP, normothermic machine perfusion; TBARS, thiobarbituric acid reactive substances.
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and can improve hepatobiliary function during rat liver 
transplantation.
Our study results are in line with recent animal experi-
ments and an observational human study where metformin 
preconditioning reduced I/R injury after myocardial infarc-
tion.2-4 These studies demonstrated that metformin admin-
istration before myocardial infarction decreased infarction 
size, preserved cardiac function, and improved survival.2-4 
To our knowledge, we are the first who report the ben-
eficial effects of metformin as preconditioning agent in a 
model of NMP and transplantation. To date, only Chai 
et al23 showed that metformin, in particular only as post-
conditioning agent, reduces hepatocyte injury after 12 
h of ex  situ hypothermic machine perfusion (4°C) in rat 
donor livers. However, their results were not confirmed in 
a transplantation model. Moreover, the perfusion time they 
used may be debatable because the current clinical applica-
tion of hypothermic machine perfusion consists of 2 h of 
perfusion.24 Therefore, it would be interesting to known 
whether metformin can have its effect in a short perfusion 
time period and especially during hypothermic conditions, 
in which reduced metabolic conditions occur. We have also 
studied the effect of metformin as postconditioning agent, 
in which metformin was added to the NMP solution (data 
not shown). Here we did not find any positive effect. We 
observed mainly lactate acidosis, low levels of ATP, and 
low bile production. Therefore we suggest that metformin 
should be intracellularly available before the ischemic 
event, which is in line with other clinical studies.25,26
As described before, metformin is able to phosphorylate 
and subsequently activate AMPK. An effect of AMPK acti-
vation is suppression of FXR transcriptional activity.10 FXR 
plays a central role in bile acid hemostasis, maintaining the 
balance between bile acid formation and transport.11 An 
impaired function of FXR can lead to an intracellular accu-
mulation of toxic bile acids and subsequently bile acid–
mediated biliary injury.12 Normally, FXR mainly induces 
BSEP expression and inhibits CYP7A1 expression.27,28 
In our study, we observed that metformin precondition-
ing before and after NMP reduces mRNA levels of both 
CYP7A1 and BSEP. Consequently, our study could not 
confirm the association between AMPK activation by met-
formin and FXR suppression. A possible explanation for 
this might be the low concentration of metformin used in 
A B
FIGURE 8. Serum markers of hepatocellular injury after rat liver transplantation. A, Posttransplant serum AST levels after 48 h of survival. 
Recipients of a metformin preconditioned donor liver showed significantly lower serum levels of AST in comparison with recipients 
without metformin preconditioned donor liver (*P < 0.05). B, Posttransplant serum LDH levels after 48 h of survival. No significant 
differences observed. Data are represented as medians with interquartile range (IQR; error bars). AST, aspartate aminotransferase; LDH, 
lactate dehydrogenase.
FIGURE 9. Histological evaluation of liver parenchyma after rat liver transplantation. A, Liver parenchyma of livers preconditioned with 
metformin. B, Liver parenchyma of livers preconditioned without metformin (controls). No pathological differences were observed. 
Coupes were stained with hematoxylin and eosin. The central vein is marked with an asterisk. Scale bars indicate 50 μm.
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our experiment during preconditioning. With precondi-
tioning, we obtained circulating metformin levels of 6 mg/L 
in situ, whereas in experiments with cultured hepatocytes 
concentrations of 165 mg/L were used and FXR suppres-
sion was observed.29 Therefore, in our study, we did not 
find evidence that 2 therapeutic doses of metformin prior 
transplantation are related to biliary injury during NMP 
and after transplantation.
Another interesting finding of our study was the relatively 
low concentration of bile salts and high bile production in 
the group with metformin preconditioning versus the group 
with saline preconditioning. The question arises if bile in the 
group with metformin preconditioning was diluted. A pos-
sible explanation may be the osmotic effect of bicarbonate 
and water. Bile flow into the bile canaliculi is dependent on 
the osmotic gradients caused by bile salts (bile salt–depend-
ent bile flow) and other solutes (bile salt–independent 
bile flow).30 With respect to the bile salt–independent bile 
flow, it has been shown that biliary bicarbonate as solute 
increases the osmotic gradient, allowing water to passively 
follow into the canaliculi.31 In the group with metformin 
preconditioning significantly more bicarbonate was secreted 
into bile during 3 h of NMP. As a result, the higher biliary 
bicarbonate production could play a role in the diluted bile 
production in the group with metformin preconditioning.
Surprisingly, in the NMP experiment, we did not find 
a significant reduction of levels of hepatocellular injury 
markers (in particular AST) between the group of met-
formin preconditioning and saline preconditioning. 
However, in the transplantation model, serum levels of 
the hepatocellular injury marker AST were significantly 
different between metformin preconditioning and the 
control group, without metformin preconditioning. A 
possible explanation could be the time period of reperfu-
sion between both experiments. The perfusion period of 
NMP was 3 h in comparison with the transplantation 
model where 48 h of reperfusion occurred. Therefore, the 
NMP perfusion period might be too short to observe a 
significant difference in the levels of hepatocellular injury 
markers between metformin preconditioning and saline 
preconditioning.
As mentioned in the Introduction, metformin protects 
against I/R injury by modulation of complex I of the res-
piratory chain in the mitochondria. Recently, a part of our 
study group (Moshage, Geng et al) has described evidence 
that metformin directly induces superoxide dismutase 
2 (SOD2) expression.32 The SOD2 enzyme is an impor-
tant enzyme in the reduction of apoptosis and cell death. 
Activation of SOD2 reduces ROS production during I/R 
with less cell death as consequence.32
Further research should be undertaken to translate our 
findings to the clinical situation. First, our perfusion and 
transplantation experiment should be performed with an 
animal model with more severe hepatobiliary cellular injury 
at baseline, for example, the usage of longer SCS times or 
a model with donation after circulatory death, to assess 
if metformin is also able to reduce cellular injury during 
ex situ NMP in these situations. Moreover, in human liver 
transplantation, it would be interesting to study outcome 
after transplantation of donor livers from diabetic donors 
who were using metformin medication, versus those 
who did not. These data could be obtained from a large 
data cohort such as the Eurotransplant database. Study 
endpoints could be serum levels of hepatobiliary injury 
markers and liver function markers the first week postop-
erative after transplantation.
In conclusion, the current study suggests that metformin 
preconditioning has a beneficial effect on donor rat liv-
ers, evidenced by improved hepatic function (increased 
bile production, higher biliary bicarbonate and bilirubin 
levels, and lower lactate levels), optimization of cellular 
energy (ATP production), and reduced hepatocyte injury 
as reflected by significantly lower levels of AST posttrans-
plantation. Our study results may form a basis for further 
clinical research, whereby the beneficial effects of met-
formin in lowering I/R injury can be studied in human liver 
transplantation with ECD livers.
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